The HER Family: A Pan Tumor Approach: A Clinical Forum

Program Overview

During this Clinical Forum℠ activity, 3 nationally recognized experts in the management of solid tumors discuss approved and emerging therapeutic approaches targeting HER2 or HER3 in patients with breast cancer, non-small cell lung cancer (NSCLC), and gastric cancer.

Credit Expired
1.00 CE Credit(s)
Expires: May 11, 2022

Target Audience

This activity is designed to meet the educational needs of medical and surgical oncologists, pathologists, oncology NPs and PAs, and pulmonologists who diagnose and manage patients with breast cancer, non-small cell lung cancer (NSCLC), and/or gastric cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Employ available data on newly approved and investigational HER2- and HER3-directed therapies for advanced breast cancer
  • Assess the therapeutic potential role and place of HER2- and HER3-targeted agents in non-small cell lung cancer (NSCLC)
  • Apply current evidence for new frontline combinations in HER2+ advanced gastric cancer, as well as new and emerging options for refractory disease

Activity Faculty


Sara M. Tolaney, MD, MPH

Associate Director, Susan F. Smith Center for Women’s Cancer
Director, Clinical Trials, Breast Oncology Center
Senior Physician
Dana-Farber Cancer Institute
Associate Professor, Medicine
Harvard Medical School
Boston, MA

Catenacci Daniel pic (1)

Daniel Catenacci, MD

Associate Professor, Department of Medicine, Section of Hematology & Oncology
Director, Interdisciplinary Gastrointestinal Oncology Program
Assistant Director, Translational Research, Comprehensive Cancer Center
The University of Chicago Medical Center & Biological Sciences
Chicago, IL

Liza Villaruz; MD;
consent signed;

Liza C. Villaruz, MD

Associate Professor, Medicine
UPMC Hillman Cancer Center
University of Pittsburgh
Pittsburgh, PA

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

© Copyright 2023. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | | (866) 770-RMEI


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources